Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant FOLFOXIRI Chemotherapy Alone for Locally Advanced Rectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Diagnosis of adenocarcinoma of the rectum~* Age: 18-70 years old~* Signed informed consent; able to comply with study and/or follow- up procedures~* Stage of the primary tumor may be determined by ultrasound or MRI~* Stage II (T3-4, N0 \[N0 is defined as all imaged lymph nodes \< 1.0 cm\]) OR stage III (T1-4, N1-2 \[with the definition of a clinically positive lymph node being any node ≥ 1.0 cm\]~* Tumor palpable by digital rectal exam OR accessible by proctoscope or sigmoidoscope~* Distal border of the tumor must be located \< 12 cm from the anal verge~* Tumor amenable to curative resection~* Adequate bone marrow, hepatic and renal function as assessed by the following laboratory requirements conducted within 7 days of starting study treatment:~* Leukocytes ≥ 3.0 x109/ L, absolute neutrophil count (ANC) ≥ 1.5 x109/ L, platelet count ≥ 100 x109/ L, hemoglobin (Hb) ≥ 9g/ dL.~* Total bilirubin ≤1.5 x the upper limit of normal (ULN).~* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 x ULN.~* Alkaline phosphatase limit ≤ 5x ULN.~* Amylase and lipase ≤ 1.5 x the ULN.~* Serum creatinine ≤ 1.5 x the ULN.~* Calculated creatinine clearance or 24 hour creatinine clearance ≥ 50 mL/ min.~* No renal disease that would preclude study treatment or follow-up~* ECOG status: 0～1~Exclusion Criteria:~* Hypersensitivity to fluorouracil, oxaliplatin or irinotecan.~* No More than 4 weeks since prior participation in any investigational drug study~* More than 4 weeks since prior participation in any investigational drug study~* Clear indication of involvement of the pelvic side walls by imaging~* With distant metastasis~* History of invasive rectal malignancy, regardless of disease-free interval~* Fertile patients must use effective contraception~* Uncontrolled hypertension~* Cardiovascular disease that would preclude study treatment or follow-up~* Lack of upper gastrointestinal tract integrity or malabsorption syndrome，active upper gastrointestinal tract bleeding~* Synchronous colon cancer~* Pregnant or nursing, Fertile patients do not use effective contraception~* Other malignancy within the past 5 years except effectively treated squamous cell or basal cell skin cancer, melanoma in situ, carcinoma in situ of the cervix, or carcinoma in situ of the colon or rectum~* No psychiatric or addictive disorders, or other conditions that, in the opinion of the investigator, would preclude study participation~* patients refused to signed informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- FOLFOXIRI (Type: EXPERIMENTAL): patients received FOLFOXIRI alone for 4 cycles before surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).